Impact of nevirapine or efavirenz coadministration and fosamprenavir daily regimen on ritonavir-boosted amprenavir pharmacokinetics in HIV infected patients

被引：0
|
作者：
Dailly, E.
Raffi, F.
Biron, C.
Allavena, C.
Jolliet, P.
机构：
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2007年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
194
引用
收藏
页码：39 / 39
页数：1
相关论文
共 50 条
  • [21] Pharmacokinetics of once-daily tenofovir, emtricitabine, ritonavir and fosamprenavir in HIV-infected subjects
    Parks, David A.
    Jennings, Harold C.
    Taylor, Christopher W.
    Acosta, Edward P.
    AIDS, 2007, 21 (10) : 1373 - 1375
  • [22] Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients
    Di Biagio, Antonio
    Rosso, Raffaella
    Loregian, Arianna
    Pagni, Silvana
    Sormani, Maria Pia
    Cenderello, Giovanni
    Palu, Giorgio
    Viscoli, Claudio
    JOURNAL OF INFECTION AND CHEMOTHERAPY, 2012, 18 (04) : 587 - 590
  • [23] Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients
    Fätkenheuer, G
    Römer, K
    Kamps, R
    Salzberger, B
    Burger, D
    AIDS, 2001, 15 (17) : 2334 - 2335
  • [24] Pharmacokinetics, safety and efficacy of ritonavir-boosted atazanavir (300/100 mg once daily) in HIV-1-infected pregnant women
    Le, Minh P.
    Mandelbrot, Laurent
    Descamps, Diane
    Soulie, Cathia
    Ichou, Houria
    Bourgeois-Moine, Agnes
    Damond, Florence
    Lariven, Sylvie
    Valantin, Marc-Antoine
    Landman, Roland
    Faucher, Philippe
    Tubiana, Roland
    Duro, Dominique
    Meier, Francoise
    Legac, Sylvie
    Bourse, Patricia
    Mortier, Emmanuel
    Dommergues, Marc
    Calvez, Vincent
    Matheron, Sophie
    Peytavin, Gilles
    ANTIVIRAL THERAPY, 2015, 20 (05) : 507 - 513
  • [25] Pharmacokinetic interaction between rifampicin and ritonavir-boosted atazanavir in HIV-infected patients
    Mallolas, J.
    Sarasa, M.
    Nomdedeu, M.
    Soriano, A.
    Lopez-Pua, Y.
    Blanco, J. L.
    Martinez, E.
    Gatell, J. M.
    HIV MEDICINE, 2007, 8 (02) : 131 - 134
  • [26] Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women
    Conradie, F.
    Zorrilla, C.
    Josipovic, D.
    Botes, M.
    Osiyemi, O.
    Vandeloise, E.
    Eley, T.
    Child, M.
    Bertz, R.
    Hu, W.
    Wirtz, V.
    McGrath, D.
    HIV MEDICINE, 2011, 12 (09) : 570 - 579
  • [27] Importance of reverse transcriptase inhibitors on the pharmacokinetics of amprenavir and ritonavir in HIV-infected patients
    Choudey, N.
    Goujard, C.
    Meynard, J. L.
    Vincent, I.
    Demarles, D.
    Taburet, A. M.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2001, 15 : 65 - 65
  • [28] Safety and Efficacy of a 36-Week Induction Regimen of Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir in HIV-Infected Patients
    Squires, Kathleen E.
    Young, Benjamin
    DeJesus, Edwin
    Bellos, Nicholas
    Murphy, Daniel
    Sutherland-Phillips, Denise H.
    Zhao, Henry H.
    Patel, Lisa G.
    Ross, Lisa L.
    Wannamaker, Paul G.
    Shaefer, Mark S.
    HIV CLINICAL TRIALS, 2010, 11 (02): : 69 - 79
  • [29] Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach
    Dailly, E.
    Raffi, F.
    Perre, P.
    Martin, J.
    Deslandes, G.
    Jolliet, P.
    HIV MEDICINE, 2009, 10 (09) : 586 - 589
  • [30] Population Pharmacokinetic Modeling and Simulation of Amprenavir Following Fosamprenavir/Ritonavir Administration for Dose Optimization in HIV Infected Pediatric Patients
    Barbour, April M.
    Gibiansky, Leonid
    Wire, Mary Beth
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (02): : 206 - 214
12345